PCRX - パシラ・ファ―マシュ―ティカルズ （Pacira Pharmaceuticals Inc.）PCRXのニュース
Pacira BioSciences reports sales of $54.9M for October (NASDAQ:PCRX) 2022/11/14 13:33:13 Seeking Alpha
Pacira BioSciences (PCRX) has reported prelim net product sales of $54.9M for October 2022. EXPAREL net product sales were $45M, compared with $42.5M for October 2021, with average…
Pacira BioSciences, Inc. (PCRX) Q3 2022 Earnings Call Transcript 2022/11/03 18:36:03 Seeking Alpha
Pacira BioSciences, Inc. (NASDAQ:NASDAQ:PCRX) Q3 2022 Earnings Conference Call November 03, 2022 08:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack -…
Assessing Pacira BioSciences’ Growth Prospects (NASDAQ:PCRX) 2022/10/20 17:00:55 Seeking Alpha
Pacira stock looks well-positioned to deliver shareholder value in the following years despite some of the near-term challenges and headwinds. Click here to see why PCRX is a buy.
Pacira BioSciences guides Q3 revenue below consensus (NASDAQ:PCRX) 2022/10/13 12:27:06 Seeking Alpha
Pacira BioSciences (PCRX) has reported prelim Q3 revenues of $167.5M, up 31% year-over-year but below consensus estimate of $171.37M.EXPAREL sales were up around 9% Y/Y in the quarter…
Pacira Pharmaceuticals Stock Shows Rising Relative Strength 2022/10/07 18:10:00 Investor''s Business Daily
Pacira Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Wedbush Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com 2021/04/08 01:05:01 Investing.com
Wedbush Stick to Their Buy Rating for Pacira Pharmaceuticals
Jefferies Stick to Their Buy Rating for Pacira Pharmaceuticals By Investing.com 2021/03/19 12:25:58 Investing.com
Jefferies Stick to Their Buy Rating for Pacira Pharmaceuticals
Leerink Partners Stick to Their Hold Rating for Pacira Pharmaceuticals By Investing.com 2021/03/02 14:48:26 Investing.com
Leerink Partners Stick to Their Hold Rating for Pacira Pharmaceuticals